(Reuters) -India’s Sun Pharmaceutical Industries said on Monday that it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology company, in a deal valued at up to $355 million.
(Reporting by Aleef Jahan in Bengaluru; Editing by Sherry Jacob-Phillips)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibility for its content.